Skip to content

Alumis Inc. ALMS Accounts Payable

Accounts Payable at other companies

Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.17B+739%

Profitability

See full
Operating margin-5,364%
Net margin-2,825.7%
FCF margin-4,487.4%

Returns & leverage

See full
Return on equity-64.6%
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Reported directly by Alumis Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayableTrade.

The official record: Alumis Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alumis Inc.'s accounts payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alumis Inc.'s accounts payable?
Alumis Inc. (ALMS) reported accounts payable of $1.43M in Q1 2026.
How has Alumis Inc.'s accounts payable changed year-over-year?
Alumis Inc.'s accounts payable increased by 166.6% year-over-year, from -$2.15M to $1.43M.